Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$2.03 - $4.28 $182,699 - $385,200
-90,000 Reduced 13.12%
595,938 $1.35 Million
Q1 2022

May 13, 2022

BUY
$4.16 - $13.72 $2.85 Million - $9.41 Million
685,938 New
685,938 $3.7 Million
Q2 2021

Jul 20, 2021

SELL
$16.52 - $20.4 $5.06 Million - $6.24 Million
-306,085 Closed
0 $0
Q4 2020

Jan 22, 2021

SELL
$15.77 - $19.03 $155,239 - $187,331
-9,844 Reduced 3.12%
306,085 $5.2 Million
Q2 2020

Jul 23, 2020

SELL
$16.86 - $23.44 $1.18 Million - $1.64 Million
-70,071 Reduced 18.15%
315,929 $7.32 Million
Q4 2019

Jan 21, 2020

SELL
$15.87 - $23.12 $63,480 - $92,480
-4,000 Reduced 1.03%
386,000 $8,000
Q3 2019

Oct 21, 2019

SELL
$16.91 - $36.27 $325,466 - $698,088
-19,247 Reduced 4.7%
390,000 $7,000
Q2 2019

Aug 01, 2019

SELL
$31.0 - $36.3 $605,864 - $709,447
-19,544 Reduced 4.56%
409,247 $14.5 Million
Q1 2019

May 02, 2019

SELL
$31.58 - $46.35 $549,965 - $807,185
-17,415 Reduced 3.9%
428,791 $14.4 Million
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $228,346 - $425,101
7,504 Added 1.71%
446,206 $14.7 Million
Q3 2018

Nov 07, 2018

BUY
$46.46 - $68.49 $14 Million - $20.7 Million
301,921 Added 220.73%
438,702 $26.7 Million
Q2 2018

Aug 14, 2018

BUY
$46.25 - $104.45 $6.33 Million - $14.3 Million
136,781 New
136,781 $6.68 Million
Q1 2018

May 09, 2018

SELL
$57.4 - $108.44 $9.24 Million - $17.5 Million
-161,000 Closed
0 $0
Q4 2017

Feb 07, 2018

SELL
$23.02 - $60.5 $2.28 Million - $5.98 Million
-98,900 Reduced 38.05%
161,000 $9.62 Million
Q3 2017

Nov 03, 2017

BUY
$17.79 - $24.0 $4.62 Million - $6.24 Million
259,900
259,900 $6.24 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.